New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
04:55 EDTALKS, ALKS, ANGO, ANGO, SNSS, SNSS, VHS, VHS, IART, IART, OCR, OCR, BKD, BKD, BAX, BAX, ARIA, ARIARBC Capital to host a conference
Healthcare Conference is being held in New York on February 26-27.
News For ALKS;ANGO;SNSS;VHS;IART;OCR;BKD;BAX;ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
13:42 EDTIARTIntegra LifeSciences price target raised to $72 from $61 at Argus
Subscribe for More Information
09:29 EDTARIAARIAD reports dismissal of class action suit in federal district court
ARIAD Pharmaceuticals announced that the United States District Court for the District of Massachusetts dismissed the shareholder class action lawsuit filed in late 2013 against the company and certain of its officers, directors and underwriters in connection with the events leading up to the temporary suspension of the marketing and commercial distribution of Iclusig on October 31, 2013, and subsequent re-launch in January 2014 based on revised U.S. prescribing information and a risk evaluation and mitigation strategy. The suit alleged that certain of the company defendants made a series of false and misleading statements regarding the safety, efficacy and commercial prospects of Iclusig. The Court granted the company’s motion to dismiss the lawsuit, concluding that the plaintiffs failed to establish that any such statements violated the company’s disclosure obligations as asserted in the complaint. “We are pleased that for the second time in as many weeks, the Court has granted our motion to dismiss what we believed from the outset was another meritless lawsuit,” said Harvey J. Berger, M.D., chairman and CEO. “Our corporate values of integrity and mutual respect are always at the forefront as we continue to focus on executing our plan for sustained revenue growth and operational excellence, leading to anticipated profitability in 2018.”
07:29 EDTIARTLeerink to hold booth tours
Leerink Booth Tours at AAOS 2015 will be held in Las Vegas on March 25-26.
07:12 EDTBAXAmerican Academy of Orthopedic Surgeons to hold annual meeting
Subscribe for More Information
March 24, 2015
10:09 EDTOCRSupreme Court overturns appeals court ruling in Omnicare case
Subscribe for More Information
09:22 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
07:37 EDTARIAARIAD announces approval of Iclusig in Israel
ARIAD Pharmaceuticals and Medison Pharma announced that the Israeli Ministry of Health has granted regulatory approval for Iclusig, ponatinib, in Israel for adult patients with: Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation Philadelphia chromosome-positive acute lymphoblastic leukaemia who are resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation. ARIAD submitted its application for Iclusig to the Israeli Ministry of Health in June 2014. Commercial launch of Iclusig is expected to occur in Q2.
March 23, 2015
08:07 EDTBKDBofA/Merrill healthcare high yield analyst has analyst/industry conference call
Healthcare High Yield Analyst Bland provides an update on the current state of the bond markets and the ability of healthcare providers to utilize debt financing on an Analyst/Industry conference call to be held on March 24 at 10 am.
March 20, 2015
07:35 EDTBKDBrookdale Senior Living price target raised to $46 from $41 at Jefferies
Subscribe for More Information
March 17, 2015
08:46 EDTBKDHCP, Brookdale announce $849M acquisition of senior housing portfolio
Brookdale Senior Living (BKD) and HCP, Inc. (HCP) announced that they have entered into a definitive agreement to acquire from Chartwell Retirement Residences a portfolio of 35 private pay senior housing communities representing 5,025 units for $849M. The Portfolio will be acquired using a RIDEA joint venture structure with HCP and Brookdale owning 90% and 10%, respectively. Brookdale has operated these communities since 2011 after its acquisition of Horizon Bay, and will continue to manage the communities post-closing under a long-term management agreement. Located in eight states with concentrations in Florida, Texas and Colorado, the Portfolio is comprised of: (i) 33 senior housing properties representing 4,792 units with a diversified care mix of 46% assisted living, 45% independent living, 5% memory care and 4% skilled nursing; and (ii) leasehold interests in two communities, which properties are wholly-owned by HCP, representing 233 units including purchase option rights exercisable in 2017. The majority of the units are located within the nation’s top 31 Metropolitan Statistical Areas. Currently 89% occupied with an average monthly rate of $3,425, the Portfolio is expected to be acquired unencumbered by third party debt, and is projected to generate a first year cash yield of approximately 6.6%. The closing of this acquisition, expected in the third quarter of 2015, is subject to regulatory approvals and other customary closing conditions. There can be no assurance that the acquisition will close or, if it does, when the closing will occur.
March 16, 2015
15:43 EDTBKDBrookdale Senior Living says has met with Sandell 'extensively'
Subscribe for More Information
15:39 EDTBKDBrookdale Senior Living confirms receipt of director nominations
Subscribe for More Information
09:15 EDTBAXCTI BioPharma shares should be bought on weakness, says Roth Capital
Subscribe for More Information
March 13, 2015
13:27 EDTARIAARIAD drug granted orphan designation as GIST treatment
ARIAD Pharmaceuticals' Iclusig was granted FDA orphan status on February 12 as a treatment of gastrointestinal stromal tumors, or GIST, according to a post to the agency's site. Reference Link
09:02 EDTBAXBaxter announces phase III trial of BAX 817 met primary endpoint
Baxter International announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa treatment for people with hemophilia A or B who develop inhibitors. The prospective, open-label, randomized, multicenter trial was designed to assess the safety and efficacy of BAX 817 in male patients ages 12 to 65 with hemophilia A or B with inhibitors over a 6-month period using on-demand therapy. The trial met its primary endpoint of successful resolution of acute bleeding episodes at 12 hours with both on-demand treatment regimens, dosing either 3x90 µg/kg or 1x270 µg/kg, with an overall success rate of 92% -- 98% and 85% in each dosing group, respectively. Further, 89% of patients in the trial achieved sustained bleeding control for all acute bleeding episodes 24 hours after infusion. No patients developed inhibitors or binding antibodies to BAX 817, and none discontinued treatment due to an adverse event. One patient was hospitalized following a traumatic muscle bleed that did not respond to BAX 817. Non-serious AEs observed in the trial were generally consistent with the underlying disease or other etiology, and were all deemed to be unrelated to treatment. Full data from the trial, including additional efficacy and safety outcomes, will be presented at a medical meeting later in 2015. The company plans to initiate regulatory submissions aligned to manufacturing expansions currently underway.
March 12, 2015
10:01 EDTALKSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:00 EDTALKSAlkermes cut to Underweight with $61 target at Morgan Stanley
Subscribe for More Information
07:14 EDTSNSSSunesis reports Q4 EPS 2c, consensus (20c)
Subscribe for More Information
06:13 EDTALKSAlkermes downgraded to Underweight from Equal Weight at Morgan Stanley
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use